Are Wall Street Analysts Bullish on Vertex Stock?

Vertex Pharmaceuticals Incorporated (VRTX), a biotechnology company headquartered in Boston, Massachusetts, specializes in developing innovative medicines for serious diseases such as cystic fibrosis, sickle cell disease, beta thalassemia, and acute pain. The company's stock has shown impressive growth, with a 41.3% increase over the past 52 weeks, outperforming the S&P 500 Index, which gained 20.2% during the same period.

In Q2 FY2026, Vertex reported a 12.5% year-over-year increase in revenue to $3.33 billion, driven by sustained demand for its CF treatments and contributions from newer therapies. The company has also raised its FY2026 revenue guidance to $13.1 billion-$13.2 billion and expects diluted EPS of $16.86 for the fiscal year, representing a 2.4% year-over-year increase.

Analysts' opinions on Vertex stock are largely positive, with 21 out of 30 covering the stock assigning a "Strong Buy" rating. However, the enthusiasm has slightly softened, with 25 analysts maintaining a "Strong Buy" rating three months ago. Despite this, the overall sentiment remains positive, providing potential upside of 1.6% based on the average price target of $560.65.